Spots Global Cancer Trial Database for A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma
Official Title: A Phase II, Multicenter, Open-Label Study of YM155 in Subjects With Unresectable Stage III or Metastatic (Stage IV) Melanoma
Study ID: NCT00281541
Conditions
Interventions
Study Description
Brief Summary: A study with YM155 for the treatment of unresectable stage III or metastatic stage IV melanoma.
Detailed Description: A phase II, multicenter, open-label study in subjects with unresectable Stage III or metastatic (Stage IV) Melanoma to evaluate the efficacy and safety of YM155
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, Tuscon, Arizona, United States
, Little Rock, Arkansas, United States
, Aurora, Colorado, United States
, Washington, District of Columbia, United States
, Atlanta, Georgia, United States
, Montclair, New Jersey, United States
, Winston-Salem, North Carolina, United States
, Pittsburgh, Pennsylvania, United States
, Salt Lake City, Utah, United States
Contact Details
Name: D. Buell, MD
Affiliation: Astellas Pharma US, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
